Clinical Trial

A Study of HC006 in Subjects With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 6, 2025 (before its estimated March 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), Immunogenicity and preliminary antitumor activity of HC006 in subjects with advanced solid tumor malignancies. This study is a first-in-human (FIH) study of HC006 in subjects with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-05.
Trial Details
NCT Number NCT06304571
Lead Sponsor HC Biopharma Inc.
Conditions Advanced Solid Tumor
Enrollment 76 participants
Start Date 2024-02-27
Primary Completion 2026-03-15 (estimated)
Study Completion 2026-07-16 (estimated)
Updated on ClinicalTrials.gov 2025-05-06